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Allogeneic stem cell transplantation (SCT) with reduced-intensity conditioning (RIC) has the potential to lead
to long-term remissions for patients with lymphoma. However, the role of RIC SCT in the treatment of lym-
phoma is still unclear. Specifically, the relative benefit of RIC SCT across lymphoma histologies and the prog-
nostic factors in this population are incompletely defined. We retrospectively analyzed the outcomes of 87
patients with advanced lymphoma who underwent RIC SCT at the Dana-Farber Cancer Institute over
a 6-year period with a homogeneous conditioning regimen consisting of fludarabine and low-dose busulfan.
Thirty-six patients had Hodgkin disease (HD) and 51 had non-Hodgkin lymphoma (NHL). Sixty-eight percent
had undergone prior autologous transplantation. The 1-year cumulative incidence of nonrelapse mortality was
13%, and the 3-year cumulative incidence of progression was 49%. The incidence of grade 3-4 acute GVHDwas
11%.The 2-year cumulative incidence of chronicGVHDwas 68%, and its developmentwas associatedwith a de-
creased risk of progression and an improved progression-free survival (PFS). Three-year overall survival (OS)
was 56% for patients with HD, 81% for indolent NHL, 42% for aggressive NHL, and 40% for mantle cell lym-
phoma. The corresponding figures for 3-year PFS were 22%, 59%, 22%, and 30%, respectively. Multivariate
analysis identified elevated pretransplantation lactate dehydrogenase (LDH) as an adverse factor for PFS, while
indolentNHLhistology was favorable. ForOS, advanced age and elevated pretransplantation LDHwere adverse
factors, whereas indolent NHL histology was favorable. Low early donor chimerism was not predictive of poor
outcome in univariate ormultivariate analyses.Moreover, progressionwas not associated with loss of chimerism.
These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the
lack of relevance of donor chimerism for outcome in this patient population.
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Allogeneic hematopoietic stem cell transplantation
(SCT) carries the theoretical promise of cure for pa-
tients with lymphoproliferative disease by relying
on a graft-versus-lymphoma (GVL) effect. However,
lymphomas are a heterogeneous group of diseases
that differ in their ability to be cured with standard or
high-dose chemotherapy, as well as in their susceptibil-
ity to GVL [1]. In the SCT experience with lymphoma
using myeloablative conditioning regimens, the de-8creased risk of relapse compared to autologous trans-
plantation was offset by a high treatment-related
mortality (TRM), such that there was no clear benefit
of SCT over autologous transplantation [2,3]. There
was also the suggestion that the benefit of allogeneic
transplantation was in avoiding tumor contamination
of the graft [4]. The use of reduced-intensity condi-
tioned (RIC) SCT led to a substantial decrease in the
incidence of TRM, apparently without a commensu-
rate increase in the risk of relapse [5], emphasizing
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optimal role and timing of RIC SCT in lymphoma
therapy are still ill defined, and vary by lymphoma sub-
type. At 1 end of the spectrum are lymphomas such as
follicular lymphoma (FL), where SCT carries the best
chance of long-term cure, but at the cost of a signifi-
cantly higher morbidity and mortality than standard
treatment for a disease that may be clinically indolent.
At the other end of the spectrum are lymphomas such
as Burkitt’s lymphoma, which seem to be minimally
susceptible to GVL, and hence, are by and large incur-
able with RIC SCT.
The published data on RIC SCT for lymphomas is
mostly made up of single-institution case series that
focus on 1 particular histology. Here we report our in-
stitution’s experience with RIC SCT using a uniform
conditioning regimen applied to 87 patients with
Hodgkindisease (HD)orB-cell non-Hodgkin lympho-
mas (NHL),with theobjectives of comparingoutcomes
among different lymphoma subgroups, extracting risk
factors for progression and survival, and examining
the relevance of donor chimerism in this setting.
METHODS
Patients
We reviewed themedical records of all consecutive
adult patients with HD orNHL (restricted to indolent
B-cell NHL, aggressive B-cell NHL, or mantle cell
lymphoma) who underwent first allogeneic SCT with
RIC at the combined Dana-Farber/Brigham and
Women’s Hospital transplant program between July
2000 and July 2006. Patients receiving umbilical cord
grafts were not included in this study. Patients with
chronic lymphocytic leukemia/small lymphocytic leu-
kemia were excluded, as their outcomes have been pre-
viously reported [6]. Eighty-seven patients met the
above criteria. Informed consent was obtained under
an institutional review board-approved protocol, and
this study was conducted in accordance with the prin-
ciples of the Declaration of Helsinki.
Transplantation
Patients were conditioned using a nonmyeloabla-
tive regimen consisting of busulfan (0.8 mg/kg/day in-
travenously for 4 days) and fludarabine (30 mg/m2/
day intravenously for 4 days), on days –5 to –2.
They received stem cells from peripheral blood (PB)
for all but 2 patients (who received bone marrow)
on day 0. For patients receiving PB stem cells, the
median dose was 7.5 106 CD341 cells/kg (range:
2.3-23.3). Most patients received a graft-versus-host
disease (GVHD) prophylaxis regimen consisting of
tacrolimus 1 sirolimus 6 low-dose methotrexate.
Acute GVHD (aGVHD) was graded according to
the modified Glucksberg scale [7,8]. Supportive care
for all patients consisted of Pneumocystis jiroveci pro-phylaxis and varicella zoster virus/herpes simplex virus
prophylaxis. Viral load monitoring was performed for
cytomegalovirus (CMV), with preemptive treatment
in cases of reactivation.
Chimerism Analysis
Donor-derived hematopoiesis was assessed after
SCT on unfractionated bone marrow aspirates or PB
on approximately day 130 (range: 20-50) and day
1100 (range: 75-120). A third sample was obtained
4-7 months after transplantation when possible. Ge-
notype of donor and recipient were determined using
DNA obtained from pretransplantation samples. Nine
short tandem repeat (STR) loci were typed using the
ABI Profiler Plus Kit (Applied Biosystems Inc., Foster
City, CA) and the ABI 310 or ABI 3130 Genetic Ana-
lyzer. Informative alleles unique to donor or recipient
were used in the determination of posttransplantation
chimerism.
Statistics
Overall survival (OS) and disease-free survival
(DFS)were calculatedusing theKaplan-Meiermethod.
OS was defined as the time from stem cell infusion to
death from any cause. Patients who were alive or lost
to follow-up were censored at the time of last follow-
up. Progression-free survival (PFS) was defined as the
time from stem cell infusion to progression or death
from any cause. Patients who were alive without
progression were censored at the time last seen alive
and progression-free. The log-rank test was used for
comparisons of Kaplan-Meier curves. Cumulative inci-
dence curves for nonrelapse death and progressionwith
or without death were constructed considering time to
progression and time to nonrelapse death as competing
risks. Competing risks analysis was also used to deter-
mine the cumulative incidence of GVHD, considering
death without GVHD as a competing risk. The differ-
ence between cumulative incidence curves in the pres-
ence of a competing risk was tested using the Gray
method [9]. Potential prognostic factors for survival,
DFS, progression, andnonrelapsedeathwere examined
in the proportional hazards model as well as in the
competing risks regression model [10]. The impact of
GVHD on outcome was examined using proportional
hazards model with GVHD as a time-dependent
variable. Interaction terms including interaction with
timewere examined in the proportional hazards regres-
sion model. Proportional hazards assumption for each
variable of interest was tested.
RESULTS
Patient Characteristics
The baseline demographic and clinical characteris-
tics of the 87 patients in this study are listed in Table 1.
Among them, 36 had Hodgkin disease (HD) (all of






Number of patients: 51 36
Age in years (median, range) 51 (34-64) 31 (18-50)
Histology:
Classical Hodgkin 36 (100)
Indolent B-NHL 13 (26)
Follicular 12 (24)
Marginal zone 1 (2)
Aggressive B-NHL 23 (45)
Diffuse large B cell 10 (20)
Transformed follicular 13 (25)
Mantle cell 15 (29)
Disease status at transplantation:
CR 14 (27) 10 (28)
PR 25 (49) 18 (50)
SD 6 (12) 2 (6)
PD 3 (6) 6 (17)
Untreated 3 (6) 0 (0)
Marrow involvement at transplantation:
Yes 7 (14) 0 (0)
No 27 (53) 9 (25)
Unknown 17 (33) 27 (75)
Best response to chemotherapy:
CR 39 (76) 33 (92)
PR 12 (24) 3 (8)
Chemosensitivity at transplantation:
Yes 42 (82) 28 (78)
No 5 (10) 4 (11)
Untreated relapse 4 (8) 4 (11)
Number of prior therapies (median, range): 4 (1-10) 4 (2-8)
Prior autologous transplantation
Yes 25 (49) 34 (94)
No 26 (51) 2 (6)
Time from diagnosis to SCT, years (median, range): 4 (0-16) 3 (1-25)
LDH pretransplantation:
Normal 46 (90) 32 (92)
Elevated 5 (10) 3 (8)
Graft source:
Peripheral blood 50 (98) 35 (97)
Bone marrow 1 (2) 1 (3)
CD34 dose (median, range):† 8.1 (2.4-23.3) 7.2 (2.3-21.6)
Match:
MRD 22 (43) 11 (31)
MUD 27 (53) 22 (61)
Mismatched related 1 (2) 0 (0)
Mismatched unrelated 1 (2) 3 (8)
Gender match:
Female -. Male 16 (31) 6 (17)
GVHD prophylaxis:
CnI ± steroids ± MMF 14 (27) 3 (8)
CnI 1 Mtx 5 (10) 9 (25)
CnI 1 Siro ± Mtx 32 (63) 24 (67)
Recipient CMV seropositive: 17 (33) 10 (28)
Donor CMV seropositive: 17 (33) 9 (25)
CR indicates complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; SCT, allogeneic hematopoietic stem cell
transplantation; MRD, matched related donor; MUD, matched unrelated donor; GVHD, graft-versus-host disease; CnI, calcineurin inhib-
itor (cyclosporine or tacrolimus); Mtx, methotrexate; Siro, sirolimus; CMV, cytomegalovirus.
*Percentages may not add to 100 because of rounding.
†Cell dose unit is 106 per kilogram of recipient weight.
Reduced-Intensity alloSCT for Lymphoma 421Figure 1. Cumulative incidence of aGVHD and cGVHD. (A) Acute GVHD; (B) cGVHD.whom had classical HD) and 51 had non-Hodgkin’s
lymphoma (NHL). Of the patients with NHL, 13
(26%) had indolent lymphoma, 23 (45%) had aggres-
sive lymphoma, and 15 (29%) had mantle cell lym-
phoma (MCL). The median age for the cohort was
46 (range: 18-64). Twenty-eight percent of the patients
were transplanted in complete remission (CR), and
49% in partial remission (PR); 20% had stable or pro-
gressive disease after their last therapy, and the remain-
ing 3% had untreated relapse. The median number of
prior lines of therapy was 4 (range: 1-10). Sixty-eight
percent of the patients had received a prior autograft
(94% of patients with HD, 15% with indolent NHL,
78% with aggressive NHL, and 33% with mantle
cell lymphoma). Thirty-eight percent of patients
were transplanted from matched related, 56% from
matched unrelated, and 6% from mismatched donors.
Engraftment
Thirty-six patients had an absolute neutrophil
count (ANC) nadir below 500 cells/mL, and 25%
a platelet nadir below 20,000 cells/mL. All patients en-
grafted, with a median time to neutrophil recovery of
13 days (range: 1-21), and a median time to platelet re-
covery of 20 days (range: 3-53). The time to neutrophil
or platelet recovery was not significantly affected by
the lymphoma histology or the CD34 cell dose.
GVHD
The cumulative incidences of aGVHDand chronic
GVHD (cGVHD) are shown in Figures 1a and b, re-
spectively. The 100-day incidence of acute GVHD
was 18% for grades 2-4 and 11% for grade 3-4. The
cumulative incidence of grade 3-4 aGVHD at 100
days was 12% for matched related donors, 10% for
matched unrelated donors, and 20% for mismatched
donors (P 5 .8). The 2-year incidence of cGVHD
was 68% (limited, 8%; extensive, 60%). When ana-
lyzed by histology, the 100-day incidences of grade 2-
4 acute GVHD were 22%, 8%, 17%, and 20% for
Hodgkin, indolent, aggressive, andmantle cell histolo-
gies, respectively (P 5 .5). The corresponding 2-yearincidences of cGVHD were 67%, 69%, 78%, and
53%, respectively (P 5 .5). In competing risks regres-
sion analyses, only the use of sirolimus in the prophy-
laxis regimen was protective for grade 2-4 acute
GVHD (hazard ratio [HR] 5 0.3 compared to calci-
neurin inhibitor1methotrexate, P5 .037). In analyses
for cGVHD, only the use of a calcineurin inhibitor
without methotrexate or sirolimus (HR compared to
calcineurin inhibitor 1 methotrexate 2.4, P 5 .036)
was significant.
The development of GVHD had a significant ef-
fect on outcomes. In proportional hazards analyses
with GVHD added as a time-dependent covariate,
grade 2-4 acute GVHD was associated with a signifi-
cantly inferior PFS (HR 5 2.6, P 5 .003) and infe-
rior OS (HR 5 4.2, P \ .0001). Chronic GVHD
was associated with improved PFS (HR 5 0.4, P 5
.004), but no significant effect on OS. We examined
interactions between GVHD and disease histology.
Although the small numbers precluded definitive
conclusions, the protective effect of cGVHD on
PFS appeared to apply to all histologies except ag-
gressive B-NHL.
Progression and Nonrelapse Mortality
The 3-year cumulative incidence of progression
(CIP) for all patientswas 49%(95%confidence interval
[CI], 37%-60%) and nonrelapse mortality (NRM) was
23% (CI, 12-33) (Table 2 and Figure 2). In competing
risks univariate modeling, the non-GVHD factors
associated with an increased incidence of progression
were number of prior therapies (HR for.4 prior ther-
apies 2.6, P 5 .042) and elevated pretransplantation
lactate dehydrogenase (LDH) (HR 5 2.7, P 5 .032).
The only factor significantly associated with NRM
was indolent NHL histology (HR 5 0, P not calcula-
ble). Although the 3-year NRM for patients with HD
appeared lower than for patients with nonindolent
NHL (15% versus 38%, respectively), this difference
was not statistically significant (P 5 .13). Elevated
LDH and indolent histology remained significant in
multivariable analyses (Table 3).
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Median follow-up for survivors was 26 months
(range: 7-73). The median follow-up was the same
for NHL and HD patients. For the entire cohort,
the 3-year PFS was 29% (CI, 17%-40%), and OS
was 53% (CI, 41%-66%) (Table 2 and Figure 3).
We examined all baseline characteristics (Table 1)
for their possible association with PFS and OS in both
univariate and multivariate analyses. HD, aggressive
B-NHL, and MCL, which had similar outcomes in
univariate analysis, were collapsed into 1 group in the
models to satisfy the proportional hazards assumption.
The factors that were significantly associated with PFS
in univariate analyses were elevated pretransplant
LDH (HR 4.2, P 5 .0004), aGVHD grades 3-4 (HR
5 4.1, P \ .0001), cGVHD (HR 5 0.4, P 5 .002)
Table 2. One-Year and 3-Year Outcomes by Histology
Histology Outcome 1-Year 3-Year
All patients PFS 53% (42-63) 29% (17-40)
OS 76% (67-85) 53% (41-66)
CIP 34% (24-45) 49% (37-60)
NRM 13% (6-20) 23% (12-33)
Indolent NHL PFS 77% (54-100) 59% (31-87)
OS 92% (78-100) 81% (56-100)
CIP 23% (0-47) 41% (11-70)
NRM 0% (NC) 0% (NC)
Aggressive NHL PFS 48% (27-68) 22% (0-45)
OS 69% (50-88) 42% (15-70)
CIP 35% (15-55) 40% (19-60)
NRM 17% (1-33) 39% (9-69)
Mantle cell NHL PFS 40% (15-65) 30% (5-55)
OS 60% (35-85) 40% (12-68)
CIP 33% (8-58) 33% (8-58)
NRM 27% (3-50) 37% (8-65)
Hodgkin PFS 53% (36-69) 22% (7-37)
OS 81% (68-93) 56% (38-74)
CIP 39% (23-55) 63% (45-81)
NRM 8% (0-18) 15% (2-28)
PFS indicates progression-free survival; OS, overall survival; CIP,
cumulative incidence of progression; NRM, cumulative inci-
dence of nonprogression mortality; NHL, non-Hodgkin lym-
phoma; NC, not calculable. Values in parentheses are 95%
confidence intervals.and disease histology. The HR for PFS for indolent
NHL, compared to other histologies, was 0.4 (P 5
.045). Indolent histology and elevated LDH remained
associated with PFS in multivariate modeling (see
Table 3). In those models, we did not include
GVHD because we included GVHD risk factors in-
cluding match and prophylaxis regimen. For OS, the
factors that were significant in univariate modeling
were indolent histology (HR 5 0.2, P 5 .027), use of
sirolimus in the GVHD prophylaxis regimen (HR
compared to calcineurin inhibitor 1 methotrexate 5
0.4, P 5 .041), elevated pretransplant LDH (HR 5
3.9, P 5 .001), and aGVHD grades 3-4 (HR 5 9.0, P
\ .0001). In multivariate modeling, age over 50, ele-
vated LDH and indolent NHL histology were signifi-
cant (see Table 3).
Response to Donor Lymphocyte Infusions (DLI)
Of the 40 patients with disease relapse or progres-
sion, 18 received DLI (among whom 2 received DLI
with expanded donor dendritic cells on a clinical pro-
tocol). The indication in all cases was disease progres-
sion or relapse. Three of those patients received DLI
as consolidation after chemotherapy. There were 2
CRs and 2 PRs, for an overall response rate of 22%.
The response rate after DLI for patients withHodgkin
disease was 15% (2 of 13, both CRs), and for patients
with aggressive NHL, 40% (2 of 5, both PRs). The
median duration of response for those 4 patients was
11 months (range: 4-35 months). Three of the 18 pa-
tients treated with DLI (17%) are alive without evi-
dence of disease relapse, at 4, 11, and 35 months
after DLI. No patient with indolent or mantle cell
lymphoma received DLI in this cohort. One patient
with diffuse large B cell lymphoma (DLBCL) received
DLI for secondary graft failure without evidence of
relapse, but the patient expired 2 months later.
Relationship of Chimerism with Outcome
Among the 87 patients, 70 (80%) had a chimerism
value available between days 20 and 50 after SCT,
from PB or marrow. The concordance between PBFigure 2. Progression and NRM, stratified by histology. (A) Cumulative incidence of progression; (B) cumulative incidence of NRM.
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neously drawn specimens was excellent, as previously
described [6]; we therefore used whichever was avail-
able in the analyses below. Of the 17 patients without
an available chimerism study, 2 died early, and the
remainder had their first value drawn after day 50.
The median day 20-50 chimerism was 97% (range:
46-100), and was similar for patients with HD (median
value 98%) and patients with NHL (median 96%).
The day 20-50 chimerism had no significant associa-
tion with PFS or OS, no matter where the cutoff value
was chosen. Neither was the chimerism value associ-
ated with any significant effect when it was added to
the multivariable models for PFS, OS, NRM, or CIP
(data not shown). This remained true when HD and
NHL were considered separately.
We also examined the relevance of chimerism in-
formation at the time of progression. Among the 40 pa-
tients with disease relapse or progression, 21 (52%)
had an available chimerism within 1 month of relapse.
The median value was 100%, and 95% of the chime-
rism values were $90%. Twenty-nine of the 40 re-
lapsed patients (73%) had a chimerism study drawn
within 2months of relapse or progression. Themedian
value was 100%, and 93% of the chimerism values
were $90%. This held true for both patients with
HD and those with NHL. Thus, progression was not
associated with a loss of chimerism. Finally, chimerism
Table 3. Summary of Multivariate Analyses
Outcome Significant Factors HR P Value
PFS Indolent NHL* 0.3 .011
Elevated LDH 3.8 .001
OS Indolent NHL* 0.1 .001
Elevated LDH 3.0 .016
Age .50 4.5 .0001
Progression Elevated LDH 2.7 .031
NRM Indolent NHL* 0 NC
Only significant factors are shown.
HR indicates hazard ratio; NC, not calculable; other abbreviations
are described in Tables 1 and 2.
*Reference group is all patients with nonindolent histology (see text).had no bearing on the result of DLI therapy. Median
chimerism pre-DLI was 100% for the 4 patients with
response to DLI (range: 100-100) as well as for the
14 patients with no response to DLI (range: 93-100).
DISCUSSION
Our results confirm that RIC SCT has the poten-
tial to induce long-term remissions in patients with
a variety of lymphomas. Our results are based on a ret-
rospective analysis of a limited and hetereogenous
sample of patients, which must be kept in mind
when interpreting the results. Nonetheless, the inclu-
sion of all lymphoma histologies in a single series with
uniform conditioning regimen and the use of multi-
variable analysis to adjust for variables such as receipt
of a prior autograft lead us to conclude that the long-
term remission rates after SCT vary significantly
across histologies, with a clearly superior outcome
for indolent histologies.
Many of the patients in our cohort received non-
standard GVHD prophylaxis regimens containing si-
rolimus, which appeared to have an influence GVHD
rates. We are currently analyzing in more details the
effect of sirolimus on transplantation outcome in this
patient population. The use of multivariable analysis
in a study of this size could certainly fail to uncover
significant differences between GVHD prophylaxis
regimens or other baseline factors, which may only
be apparent in larger studies.
Patients with Hodgkin disease in our series had
a low rate of PFS (mostly because of a high rate of pro-
gression), with a large difference between PFS andOS.
This is consistent with other groups’ experiences [11].
As was the case for patients with aggressive lymphoma,
most (94%) patients with HD in our study had failed
a prior autologous transplantation, implying very ag-
gressive disease. Yet there is in our series some evidence
of aGVL effect (as suggested by the protective effect of
cGVHD and by the ability to achieve durable re-
sponses with DLI), which has also been previously
reported [12-14]. Intensifying the conditioning regi-
men before allogeneic transplantation has not beenFigure 3. PFS and OS, stratified by histology. (A) PFS; (B) OS.
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lenge may therefore be to harness the GVL effect in
time to prevent progression without relying on condi-
tioning intensity to lengthen posttransplantation
remission. Immune manipulations that target the in-
teraction between the tumor cells and the immune
system after transplantation may be a reasonable strat-
egy in this setting.
The survival rate for indolent NHL patients in our
series is comparable to previously published results
[5,15-19]. The better outcome of those patients is not
simply a function of amore indolent behavior after pro-
gression, because both PFS and OS were superior for
patients with indolent NHL in multivariable analyses.
It is also unlikely that this reflects a longer time to pro-
gression for indolent NHL, given how heavily pre-
treated our patients were, with a median time to last
relapse of 5.5 months. The trend toward a lower PFS
with heavier pretreatment, combined with the very
favorable NRM, suggest that RIC SCT may warrant
consideration earlier in the treatment course of patients
with relapsed indolent NHL.
In our series, patients with aggressive NHL had
a low rate of PFS, which resulted from both a high
risk of NRM and a high risk of progression. Prior stud-
ies have reported PFS or event-free survival (EFS)
close to or slightly higher than ours [5,15,18-22].
Comparative studies have also shown that patients
with aggressive NHL do not do as well after RIC
SCT as patients with indolent NHL [5,15,21]. In our
series, as in the study of Rezvani and colleagues [19],
patients with transformed indolent lymphoma had
a worse outcome than patients with nontransformed
indolent lymphoma, comparable to that of patients
with de novo aggressive histologies. The poorer out-
come of patients with aggressive NHL occurred de-
spite the fact that those patients were not more likely
to have chemorefractory disease in our cohort. Our re-
sults suggest that aggressive NHL histologies may be
less sensitive to theGVL effect, as evidenced by the ap-
parent absence of a protective effect of cGVHD on
progression in this subgroup. This has also been noted
in a series of patients with aggressive NHL [23] treated
with myeloablative SCT. It must be remembered that
many of the patients with aggressive NHL in our study
(78%) had failed a prior autograft, whichmay select for
more aggressive disease. Nonetheless, based on our re-
sults and those of others, and at least as long as autol-
ogous transplantation remains the standard of care for
patients in second remission, it may be unlikely that
changes in the timing of allogeneic transplantation,
in the intensity of conditioning regimen, or in the
intensity of posttransplantation immunosuppression
(with our current armamentarium) will fundamentally
alter the outcome of RIC SCT for this disease, unless
new ways to augment the antilymphoma immune re-
sponse can be found.For patients with mantle cell lymphoma, alloge-
neic stem cell transplantation has been documented
to lead to long-term remissions, with either myeloa-
blative or nonablative conditioning [24]. However, re-
ported outcomes vary widely [25,26]; thus, whereas it
is clear that this entity is sensitive to GVL, it remains
unclear whether conditioning regimen intensity is im-
portant, and more importantly what the patient char-
acteristics are that would predict for a good outcome
after RIC SCT.
It may be surprising that chemosensitivity was not
a significant factor for progression or PFS in our series,
as has been described previously for both myeloabla-
tive and nonablative SCT [2,21]. This discrepancy
may be partly explained by patient selection, in that pa-
tients selected for RIC SCT despite chemorefractori-
ness may have less aggressive disease progression or
smaller tumor bulk, and may hence have a better out-
come than unselected refractory patients. Moreover,
the methods used for restaging prior to RIC SCT (in
particular, in the use of PET versus CT scan and the
use of bone marrow biopsy) differed among patients
in our study; this could have obscured a possible differ-
ence in outcome between chemosensitive and chemo-
refractory patients.
Our study also calls into question the prognostic
relevance of donor chimerism in the setting of RIC
SCT for lymphoma. Indeed, even with our low-inten-
sity conditioning, most patients achieved full donor
chimerism early. This did not correlate with transplan-
tation outcome. More importantly, there was no ap-
parent loss of chimerism at the time of disease
relapse or progression, and no predictive value of chi-
merism for DLI outcome. Those results suggest that
chimerism (at least total leukocyte chimerism) is not
an acceptable surrogate for outcome in RIC SCT for
lymphoma, and should perhaps not be used to guide
treatment decisions other than in the context of graft
failure.
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